For more details please visit:
Local talent pool
Counting on a yearly total of 170,000 highly skilled young possible employees or consumers, Romania offers solid possibilities to support the EMA principles to engage young persons in work or constant dialogue and interaction through the Agency’s different activities.
With 36 medical school graduates per each 100,000 inhabitants, Romania is top ranked at global level in terms of medical school graduates per capita (by comparison, the United States has 6.5 graduates and UK, 9.3 graduates per 100,000).
Bucharest counts for more than 1600 medical university teaching staff and around 10,000 medical, dental and pharmacy students.
More than 70% of foreign students studying in Romania (5,678) are enrolled in universities of medicine and pharmacy.
This provides the EMA with young, very flexible and highly skilled potential work force, adapted to short- or long-term assignments, with modern views of the global labour market.
The local private market is centred on multinational firms, with a potential of several million EU in IT activity. For 2017, there are clear signs of a rising local IT market, increasingly educated IT managers/CEOs, as well as top executives. Based on the number of employees and turnover, the first 5 IT companies in Bucharest and Romania are multinationals like Oracle, IBM, Ericsson Telecommunications, Microsoft, Atos IT Solutions and Services.
Romania ranks fourth worldwide in terms of medals awarded in all times International IT scholar competitions.
Romanian research heritage
Romania has long-lasting tradition in medical and pharmaceutical research, with bright, talented researchers who had a significant contribution to the development of a wide range of medicine and pharmacy fields, some of them with a global influence on the healthcare:
George Emil Palade, Romanian Nobel Prize laureate, for physiology and medicine, won it in (1974). He is considered to be the father of modern cell biology.
Ana Aslan, developed Gerovital, vitamin H3, from 1952 patented in 30 countries.
The pharmaceutical industry in Romania is thriving, with an average revenue of approx. 2 billion euro per year. The value chain in the pharmaceutical industry has increased significantly in the past decade in all segments, contributing with over 1% to the GDP.
Embrace the latest technologies
Nowadays, Romania is a country with high perspectives in the research and development area, counting more than 30,000 people working in research fields, out of which 18,000 high skilled researchers.
A country with high perspectives in the research and development area, Romania counts more than 30,000 people working in research fields, out of which 18,000 highly skilled researchers.
The Extreme Light Infrastructure – Nuclear Physics (ELI-NP), the most advanced research facility in the world, focusing on the study of photonuclear physics and its applications, is placed in Romania (only 12 km outside Bucharest).
The infrastructure will create a new European laboratory with a broad range of sciences covering frontier fundamental physics, new nuclear physics and astrophysics as well as applications in nuclear materials, radioactive waste management, material sciences and life sciences.
The “Victor Babes” National Institute – the “telocytes group in Bucharest” has discovered a new type of interstitial cells – the telocytes, with possible implications in transmission of signals initiating regeneration. Romania is the first country in Europe in terms of telemedicine.
ELI-NP – a very high intensity laser system, with two 10 PW laser arms able to reach intensities of 1023 W/cm2 and electrical fields of 1015 V/m, is going to be the most advanced research facility in the world focusing on the study of photonuclear physics and its applications, and the most brilliant tunable gamma-ray beam. Situated in Magurele, only 12 km from downtown Bucharest, the users of the ELINP facility benefit from all of the infrastructures and services provided within the metropolitan area.
``Victor Babes`` National Institute
Telocytes are a new type of interstitial cells, discovered by the famous “telocytes group in Bucharest”, created by Laurentiu M. Popescu, with possible implications in the transmission of the signals that initiate the regeneration. In 2012, telocytes became an internationally registered brand. The most active countries in telocytes research are: China, Italy, Spain, Germany, Belgium, Singapore or USA. The role of telocytes is today only supposed, but most likely, their still unknown functions are closely correlated with the particularities of their structure.